Method of predicting a predisposition to QT prolongation
The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
1. A method of administering a compound to a human individual, wherein the compound is iloperidone, a metabolite of iloperidone, or a pharmaceutically acceptable salt of iloperidone or metabolite thereof, the method comprising:
determining the individual's FAM13A1 (family with sequence similarity 13, member A1) genotype at a single nucleotide polymorphism (SNP) locus selected from the group consisting of rs17014687, rs17014546, rs6814344, rs13131633, and rs4544678; and
administering a first quantity of the compound if the individual's FAM13A1 genotype is associated with increased risk of QT prolongation and is TT at rs17014687, non-CC at rs17014546, non-TT at rs6814344, non-GG at rs13131633, or non-AA at rs4544678, or
administering a second quantity of the compound if the individual's FAM13A1 genotype is non-TT at rs17014687, CC at rs17014546, TT at rs6814344, GG at rs13131633, or AA at rs4544678; wherein the first quantity of the compound is less than the second quantity of the compound.
2. The method of claim 1 , further comprising determining the individual's CYP2D6 genotype.
3. The method of claim 1 , wherein the compound is iloperidone or a pharmaceutically acceptable salt thereof.
4. A method of administering a compound to a human individual suffering from long QT syndrome (LQTS), wherein the compound is iloperidone, a metabolite of iloperidone, or a pharmaceutically acceptable salt of iloperidone or metabolite thereof, the method comprising:
determining the individual's FAM13A1 (family with sequence similarity 13, member A1) genotype at a single nucleotide polymorphism (SNP) locus selected from the group consisting of rs17014687, rs17014546, rs6814344, rs13131633, and rs4544678; and
administering a first quantity of the compound if the individual's FAM13A1 genotype is associated with increased risk of QT prolongation and is TT at rs17014687, non-CC at rs17014546, non-TT at rs6814344, non-GG at rs13131633, or non-AA at rs4544678, or
administering a second quantity of the compound if the individual's FAM13A1 genotype is non-TT at rs17014687, CC at rs17014546, TT at rs6814344, GG at rs13131633, or AA at rs4544678; wherein the first quantity of the compound is less than the second quantity of the compound.
5. The method of claim 4 , further comprising determining the individual's CYP2D6 genotype.
6. The method of claim 4 , wherein the compound is iloperidone or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 , wherein the compound is a metabolite of iloperidone, wherein the metabolite is 1-[4-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]ethanol, or a pharmaceutically acceptable salt thereof.
8. The method of claim 4 , wherein the compound is a metabolite of iloperidone, wherein the metabolite is 1-[4-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]ethanol, or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 , wherein the second quantity of the compound is 24 mg/day.
10. The method of claim 4 , wherein the second quantity of the compound is 24 mg/day.